

## Original Research Article

1  
2  
3 **Multi-drug resistance pattern of *Staphylococcus aureus* from Paediatric ward, General**  
4 **Hospital, Ikot-Ekpaw, Mkpato Enin LGA, Akwa-Ibom State, Nigeria.**

### 7 **ABSTRACT**

8 **AIM:** This study evaluated the Multi-drug resistance (MDR) pattern of *Staphylococcus aureus*  
9 from a paediatric ward and was conducted using standard clinical microbiological procedures.

10 **LOCATION AND DURATION OF STUDY:** The study was carried out on infant samples  
11 collected from the Paediatric ward, General Hospital, Ikot-Ekpaw, Mkpato Enin LGA, Akwa-  
12 Ibom State, Nigeria, over three (3) months period.

13 **DESIGN OF STUDY:** Hundred swab-samples were inoculated on Mannitol salt agar. Positive  
14 growths were further biochemically confirmed for *Staphylococcus aureus*. Confirmed isolates  
15 were then used for MDR evaluation.

16 **RESULT AND INTERPRETATION:** Of the 100 samples from skin, wound, ear, throat and  
17 nose swabs, 28 isolates were confirmed as *S. aureus* and were subjected to a range of selected  
18 commercially available antibiotics like: amoxicillin, ampiclox, chloramphenicol, ciprofloxacin,  
19 erythromycin, gentamicin, levofloxacin, norfloxacin, rifampicin and streptomycin, to evaluate  
20 their susceptibilities. The wound swabs gave the highest isolate percentage yield (32%) followed  
21 by skin swabs (29%). Susceptibility results showed that amoxicillin and ampiclox were more  
22 resisted by the isolates, while ciprofloxacin, levofloxacin and norfloxacin were more effective  
23 against the isolates. The Multiple antibiotics resistance (MAR) indices showed that 85.7% of the  
24 isolates had confirmed multi-drug resistance status, with 60.7% of the isolates showing  
25 resistance to between four or more of the tested antimicrobials. MAR indices revealed that  
26 96.4% of the isolates had 0.3, indicating that the resistance resulted from isolates that adapted to  
27 the tested drugs due to some form of abuse. Restricted use of these drugs would help curtail the  
28 high resistance currently observed amongst microorganisms.

29 Key words: multi-drug resistance, *Staphylococcus aureus*, multiple antibiotics resistance index,  
30 susceptibility test, nosocomial infections

### 32 **INTRODUCTION**

33 Microbes do manifest themselves in three ways, through substance spoilage, fermentation of  
34 organic and inorganic matters and causation of ailments. Different microorganisms, with their  
35 different mode of aetiology, causing different types of ailments, will require different methods

36 and effective drugs for treatments. Continuous deployment of antimicrobial drugs in treating  
37 microbial infections has led to the emergence of resistance amongst various strains of  
38 microorganisms [1, 2]. Multi-drug resistance (MDR) literally means 'being resistant to more than  
39 one antimicrobial agent', although a standardized definition has not yet been agreed upon by the  
40 medical community. There are currently other definitions that are used to characterize multidrug  
41 resistance. The most practical definition used for Gram-positive and Gram-negative bacteria is  
42 'resistance to three or more antimicrobial classes according to Magiorakos *et al.* [3]. MDR could  
43 also be defined as the insensitivity or resistance of a microorganism to administered  
44 antimicrobial medicines (which are structurally unrelated and have different molecular targets)  
45 despite earlier sensitivity to the same medicines [4].

Comment [AC11]: Patterns deleted.

46 According to Nikaido [5], multidrug resistance in bacteria cells come about by their  
47 accumulation of resistance (R) plasmids or transposons, or genes, with each coding for resistance  
48 to a specific agent, and/or by the action of multidrug efflux pumps, each of which can pump out  
49 more than one drug type. This MDR abilities lead to ineffective ailment treatment, resulting in its  
50 persistence, infections spread and high cost [2, 6].

51 The hospital environment has been said to be an active reservoir for infectious microorganisms,  
52 being the meeting point for people with diverse disease etiological agents and susceptible  
53 individuals [7, 8, 9]. Nikaido [5] mentioned that *Staphylococcus aureus* has a known  
54 nosocomial, multi-drug-resistant strain referred to as the methicillin-resistant *Staphylococcus*  
55 *aureus* (MRSA). MRSA was initially controlled but currently is also resistant to other  
56 antimicrobials like the aminoglycosides, chloramphenicol, lincosamides, macrolides and  
57 tetracycline [1]. This study was conducted as part of evidence to buttress the efficacy of  
58 *Staphylococcal* infections in young children and the scale to which MDR pathogens are  
59 becoming threats to the health of the younger generation amongst the Mkpato Enin, Akwa-Ibom  
60 State populace.

Comment [AC12]: Italics removed.  
Staphylococcal is not a name of an organism.

61

## 62 MATERIALS AND METHODS

### 63 Study Facility, Group and Sample Collection

64 The study facility is in a growing town and services a couple of adjoining communities, with a  
65 number of established institutions, stable commerce and ever growing population. The General

66 Hospital, Ikot-Ekpaw, in Mkpata Enin LGA, Akwa-Ibom State, South-South Nigeria, has Out-  
67 patient department, Post-natal ward, Paediatric ward and servicing laboratories. The study  
68 focused on children aged 1-15 years.

69 One hundred (100) samples from skin, nostrils, wound, throat and ear were collected over a  
70 period of three months using sterile swabs. Once gotten, the swabs were labelled, placed in an  
71 ice pack and taken to the Microbiology laboratory, Akwa-Ibom State University.

Comment [AC13]: There is nothing like sterile swab samples.

## 72 Sample Analysis

73 The samples were dipped into peptone water and incubated at 37°C for 24 hours. A loopful from  
74 each sample was streaked on separate Mannitol salt agar (MSA) plates and incubated at 37°C for  
75 24 hours. Discrete golden yellow colonies were subcultured, purified and preserved. Only Gram  
76 positive cocci bacterial colonies were further tested for catalase and coagulase.

## 77 Antibiotics Susceptibility Test

78 Confirmed *Staphylococcus aureus* isolates were tested for their susceptibilities to various  
79 selected commercial antibiotic drugs like Ciprofloxacin, Erythromycin, Levofloxacin,  
80 Gentamicin, Ampiclox, Rifampicin, Amoxicillin, Streptomycin, Norfloxacin and  
81 Chloramphenicol. Overnight cultures using Kirby-Bauer method [10] were inoculated on  
82 Mueller-Hinton agar (Oxoid, UK), cultures adjusted to 0.5 McFarland standard. After pre-  
83 diffusion, the plates were incubated at 37°C for 24 hours. Diameter of zones of inhibition (IZDs)  
84 produced by the antibiotics were measured and recorded in millimeter. Thereafter, the Multiple  
85 antibiotics resistance (MAR) index was determined for each isolate using the formula  $MAR =$   
86  $x/y$ , where  $x$  is the number of antibiotics to which test isolate displayed resistance and  $y$  is the  
87 total number of antibiotics to which the test organism has been evaluated for sensitivity [11, 12].

88

## 89 RESULTS AND DISCUSSIONS

90 Result for the prevalence of *S. aureus* is as shown in Table 1. The result table shows that of the  
91 28 samples that yielded *S. aureus*, wound samples had the highest number, which was followed  
92 by samples from children skin swabs. The least number of confirmed *Staphylococcus aureus*  
93 isolates were from the ear swabs.

94 The susceptibility pattern of the 28 confirmed test isolates to the selected commercially available  
95 drugs (amoxicillin, ampiclox, chloramphenicol, ciprofloxacin, erythromycin, gentamicin,  
96 levofloxacin, norfloxacin, rifampicin and streptomycin) is as shown in Figure 1. Ciprofloxacin

97 was the most effective drugs against the test organism, followed by Levofloxacin and  
 98 Norfloxacin. Confirmed *Staphylococcus aureus* isolates had high resistance for Amoxicillin,  
 99 closely followed by their resistance for Ampiclox.


100

101

**Table 1: Prevalence of *Staphylococcus aureus* from clinical samples**

Type of Specimen	Sample Size	Number of <i>S. aureus</i> isolated	Total percentage
Skin	20	8	29
Nose	20	5	18
Wound	20	9	32
Throat	20	4	14
Ear	20	2	7

102



**Figure 1: Antibiotics susceptibility pattern of *Staphylococcus* strains from clinical sample**

103

104 **KEY:** R= Resistant, S= Sensitive, CPX= Ciprofloxacin, E= Erythromycin, LEV= Levofloxacin, CN= Gentamicin,  
 105 APX= Ampiclox, RD= Rifampicin, AMX= Amoxicillin, S= Streptomycin, NB= Norfloxacin, CH=  
 106 Chloramphenicol

107

108 Table 2 has the multiple antibiotics resistance (MAR) index result which shows that 85.7% of the  
109 confirmed test isolates were multi-drug resistant (showing resistance to three or more classes of  
110 antibiotics). Only 14.3% of the isolates showed resistance to only two classes of antibiotics.  
111 Results from this study show that 60.7% of test isolates had resistance for four or more  
112 antibiotics drugs. MAR index value for 96.4% of the test isolates reveal cases of source drug  
113 abuse.

**Table 2: Antibiotic Resistance Pattern and MAR index of *Staphylococcus aureus***

S/N	ISOLATE CODE	Antibiotic Resistant Pattern	MARI	Antibiotic Resistant Class
1	S9	RD, S	0.2	RIF, AMG
2	S8	APX, AMX, CH	0.3	PEN, CHL
3	N3	LEV, APX, AMX	0.3	QUI, PEN
4	W1	CN, AMX, CH	0.3	AMG, PEN, CHL
5	W9	APX, AMX, S	0.3	PEN, AMG
6	S10	CN, APX, RD, AMX	0.4	AMG, PEN, RIF
7	T6	E, APX, AMX, NB	0.4	MAC, PEN, QUI
8	T8	CPX, E, APX, AMX	0.4	QUI, MAC, PEN
9	S2	E, APX, RD, AMX, S	0.5	MAC, PEN, RIF, AMG
10	S3	E, CN, APX, AMX, S	0.5	MAC, AMG, PEN
11	N1	E, CN, APX, AMX, CH	0.5	MAC, AMG, PEN, CHL
12	N2	CN, APX, AMX, S, CH	0.5	AMG, PEN, CHL
13	W2	E, LEV, APX, AMX, S	0.5	MAC, QUI, PEN, AMG
14	W5	E, APX, AMX, S, CH	0.5	MAC, PEN, AMG, CHL
15	W6	CN, APX, AMX, S, CH	0.5	AMG, PEN, CHL
16	W7	APX, AMX, S, NB, CH	0.5	PEN, AMG, QUI, CHL
17	W10	E, LEV, APX, AMX, S	0.5	MAC, QUI, PEN, AMG
18	T3	E, APX, AMX, S, CH	0.5	MAC, PEN, AMG, CHL
19	E5	E, CN, APX, RD, AMX	0.5	MAC, AMG, PEN, RIF
20	S1	E, CN, APX, RD, AMX, S	0.6	MAC, AMG, PEN, RIF
21	S5	E, LEV, APX, RD, AMX, S	0.6	MAC, QUI, PEN, RIF, AMG
22	S6	CN, APX, RD, AMX, S, CH	0.6	AMG, PEN, RIF, CHL
23	N5	CPX, CN, APX, AMX, S, CH	0.6	QUI, AMG, PEN, CHL
24	W8	E, CN, APX, AMX, S, NB	0.6	MAC, AMG, PEN, QUI
25	N8	E, CN, APX, RD, AMX, S, NB	0.7	MAC, AMG, PEN, RIF, QUI

26	W3	LEV, CN, APX, RD, AMX, S, NB	0.7	QUI, AMG, PEN, RIF
27	T2	E, CN, APX, RD, AMX, S, CH	0.7	MAC, AMG, PEN, RIF, CHL
28	E9	CPX, E, CN, APX, AMX, S, CH	0.7	QUI, MAC, AMG, PEN, CHL

**KEY:** CPX= Ciprofloxacin, E= Erythromycin, LEV= Levofloxacin, CN= Gentamicin, APX= Ampiclox, RD= Rifampicin, AMX= Amoxicillin, S= Streptomycin, NB= Norfloxacin, CH= Chloramphenicol, MARI= Multiple antibiotic resistance index, RIF= Rifamycins, AMG= Aminoglycosides, PEN= Penicillins, CHL= Chloramphenicol, MAC= Macrolides, QUI= Quinolones

114 Data for isolate occurrence and confirmation showed that there were more confirmed  
 115 *Staphylococcus* isolates from wound swab-samples, followed by skin swab-samples. Parta *et al.*  
 116 [13] also recorded very high *Staphylococcus* number from wound swabs. This high isolate-  
 117 numericals is suggestive of the exposed nature of the sampling points. This is supported by  
 118 findings presented by Nimmo *et al.* [14], who found more *Staphylococcus* isolates on exposed  
 119 body surfaces than the internal parts. While uncovered wounds have sticky surfaces and the skin  
 120 is continuously exposed, it is therefore easy for such high microbial numbers to be recorded.

121 Susceptibility data showed that all the confirmed and tested isolates resisted two or more  
 122 antimicrobials. Qureshi *et al.* [15] also isolated MRSA that resisted multiple anti-microbials from  
 123 hospital specimens. This study's result showed a higher MDR percentage than the "nearly half"  
 124 proportion reported by Nimmo *et al.* [14].

125 More than 96.4% of the MAR indices were 0.3 from this study evaluation. This assertion is  
 126 indicative that resistance to these multiple drugs come from over exposure of the isolates to  
 127 drugs, making them adapt or resistant to them with recurrent treatments. The high case of MDR  
 128 amongst microorganisms can drastically be reduced by mere restricting the indiscriminate and  
 129 readily availability of these drugs over the counter [14].

130

### 131 CONCLUSION

132 In conclusion, many studies have shown that prolonged stays in hospitals increases the risk for  
 133 the colonization or infection with MDR *Staphylococcus aureus*. This reflects an inherent risk in  
 134 acquiring MDR organisms through environmental contaminations and hospital stay conditions.  
 135 With infant patients, another potential transmission route is through infected staff members  
 136 handling and this calls for special care [16, 17].

137

138 The isolation of MDR *Staphylococcus aureus* from infant patients is a call for the proper  
139 implementation of contact precautions during hospitalization especially in health facilities across  
140 developing countries [16, 18].

#### 141 **Ethical consideration**

142 The study was approved by the ministry of health, Akwa Ibom State. Permission was obtained  
143 from General Administration of the General hospital prior to collecting any data. Participants'  
144 privacy and confidentiality have been assured (no names have been used, only numbers were  
145 used) and all data and results have been handled and treated confidentially.

146

#### 147 **REFERENCES**

148 1 McIntosh, J. (2018). Antibiotic resistance: What you need to know. Medical news today,  
149 (<https://www.medicalnewstoday.com/articles/283963.php>).

150 2 Tanwar, J., Das, S., Zeeshan, F. and Hameed, S. (2014). Multidrug Resistance: An Emerging  
151 Crisis. *Interdisciplinary Perspectives on Infectious Diseases*, 7 pages.

152 3 Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G.,  
153 Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D. L., Rice, I. B.,  
154 Stelling, J., Struelens, M. J., Vatopoulos, A., Weber J. T. and Monnet, D. L. (2012). Multidrug-  
155 resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert  
156 proposal for interim standard definitions for acquired resistance. *Clinical Microbiology and*  
157 *Infection*, 18, 268–281.

158 4 Singh, V. (2013). Antimicrobial resistance. *In: Microbial Pathogens and Strategies for*  
159 *Combating Them: Science, Technology and Education*, FormatexResearchCenter, 1, 291-296.

160 5 Nikaido, H. (2009). Multidrug Resistance in Bacteria. *Annual Review of Biochemistry*, 78,  
161 119–146.

162 6 WHO (2014). *Antimicrobial Resistance Global Report on Surveillance*. Geneva, Switzerland:  
163 World Health Organization.

164 7 Zhanel, G. G., DeCorby, M., Laing, N., Weshnowski, B., Vashisht, R., Taylor, F., Nichol, K.  
165 A., Wierzbowski, A., Baudry, P. J., Karlowsky, J. A., Lagace-Wiens, P., Walkty, A.,  
166 McCracken, M., Mulvey, M. R. and Johnson, J. (2008). The Canadian Antimicrobial Resistance  
167 Alliance (CARA), and Hoban DJ (2008). Antimicrobial-resistant pathogens in intensive care  
168 units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-  
169 2006. *Antimicrobial Agents and Chemotherapy*, 52, 1430-1437.

170 8 Rhomberg, P. R., Fristoche, T. R., Sader, H. S. and Jones, R. N. (2006). Antimicrobial  
171 susceptibility pattern comparisons among intensive care unit and general ward Gram negative  
172 isolates from meropenem yearly susceptibility test Information programme (USA). *Diagnostic*  
173 *Microbial Infectious Disease*, 56, 57-62.

- 174 9 O'Brien, F. G., Pearman, J. W., Gracey, M., Riley, T. V. and Grubb, W. B. (1999). Community  
175 strain of methicillin-resistant *Staphylococcus aureus* involved in a hospital outbreak. *Journal of*  
176 *Clinical Microbiology*, 37(9):2858–2862.
- 177 10 Hudzicki, J. (2009). Kirby-Bauer disk diffusion susceptibility test protocol. *American Society*  
178 *for Microbiology*, 23 pages.
- 179 11 Tula-Sanchez, A. A., Havas, A. P., Alonge, P. J., Klein, M. E., Doctor, S. R., Pinkston, W.,  
180 Glinsmann-Gibson, B. J., Rimsza, L. M. and Smith, C. (2013). A model of sensitivity and  
181 resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-  
182 dependent kinase inhibitors. *Cancer Biology and Therapy*, 14(10): 949-961.
- 183 12 Olayinka, A. T., Onile, B, A. and Olayinka, B. O. (2004). Prevalence of multi-drug resistance  
184 (MDR) *Pseudomonas aeruginosa* isolates in surgical units of Ahmadu Bello University  
185 Teaching Hospital, Zaria, Nigeria: An indication for effective control measures. *Annals of*  
186 *African Medicine*, 3(1): 13-16.
- 187 13 Parta, M., Goebel, M., Matloobi, M., Stager, C. and Musher, D. M. (2009). Identification of  
188 Methicillin-Resistant or Methicillin-Susceptible *Staphylococcus aureus* in Blood Cultures  
189 and Wound Swabs by GeneXpert. *Journal of Clinical Microbiology*, 47(5):1609–1610.
- 190 14 Nimmo, G. R., Pearson, J. C., Collignon, P. J., Christiansen, K. J., Coombs, G. W., Bell, J.  
191 M., McLaws M. L. and the Australian Group on Antimicrobial Resistance (2011).  
192 Antimicrobial susceptibility of *Staphylococcus aureus* isolated from hospital in-patient.  
193 *Community Disease Intelligence*, 35(3):237–243.
- 194 15 Qureshi, A. H., Rafi, S., Qureshi, S. M. and Ali, A. M. (2004). The Current Susceptibility  
195 Patterns of Methicillin Resistant *Staphylococcus aureus* to Conventional Anti-Staphylococcus  
196 Antimicrobials at Rawalpindi. *Pakistan Journal of Medical Science*, 20(4): 361-364.
- 197 16 Buke, C., Armand-Lefevre, L., Lolom, I., Guerinot, W., Deblangy, C., Ruimy, R.,  
198 Andremont, A. and Lucet J. C. (2007). Epidemiology of multidrug-resistant bacteria in patients  
199 with long hospital stays. *Infection Control and Hospital Epidemiology*, 28(11):1255–1260.
- 200 17 Maamar, E., Ferjani, S., Jendoubi, A., Hammami, S., Hamzaoui, Z., Mayonnove-Coulangue,  
201 L., Saidani, M., Kammoun, A., Rehaïem, A., Ghedira, S., Houissa, M., Boutiba-Ben Boubaker,  
202 I., Slim, A. and Dubois, V. (2016). High prevalence of gut microbiota colonization with broad-  
203 spectrum cephalosporin resistant enterobacteriaceae in a tunisian intensive care unit. *Frontiers in*  
204 *Microbiology*, 7, 1859.
- 205  
206 18 Harbarth, S., Sax, H., Fankhauser-Rodriguez, C., Schrenzel, J., Agostinho, A. and Pittet, D.  
207 (2006). Evaluating the probability of previously unknown carriage of MRSA at hospital  
208 admission. *American Journal of Medicine* 119(3):275.e15-e23